title: Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C.
abstract: Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide - fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M (SCCA-IgM), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-IgM may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology.
authors.affiliation: Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35122 Padua, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Martini
authors.affiliation: Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35122 Padua, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallotta
authors.affiliation: Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35122 Padua, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pontisso
authors.affiliation: Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35122 Padua, Italy.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Fassina
keywords: Cirrhosis; Hepatitis C virus; Prognosis; Squamous cell carcinoma antigen-immunoglobulins M; Treatment